OBJECTIVES
Series Objectives
• Understand appropriate diagnosis of PsO and PsA symptoms from cross-disciplinary perspectives to ensure early intervention
• Employ appropriate strategies to diagnose and treat comorbidities associated with PsD
• Outline the safety, efficacy, and role of current and emerging treatments in addressing both skin and joint symptoms for PsO and PsA
• Identify tools that different providers can use when screening for comorbid conditions related to PsO and PsA
• Recognize and incorporate best practices (clinical pearls) regarding assessment, management, and treatment options for PsD
• Applying patient-centric, collaborative care and appropriate shared management model for the treatment of individuals living with PsD and how to establish an integrated practice setting or collaboration.

PRESENTATIONS AND SPEAKERS
Presentation #1
Collaborative Care in Psoriatic Disease

AVAILABLE CREDITS/POINTS
Credit Designation
The National Psoriasis Foundation designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Psoriasis Foundation designates this live activity for a maximum of 4 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE STATEMENTS 
Series Disclosures
G. Michael Lewitt, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
• AbbVie, Eli Lilly & Company, Janssen - Consulting - Relationship Has Not Ended
• AbbVie, Eli Lilly & Company, Janssen, Pfizer, Galderma, UCB, Ortho - Dermatologics - Speaking - Relationship Has Not Ended
• AbbVie, Janssen, Dermavant - Advisory Committee Member - Relationship Has Not Ended
• Galderma - Contracted Research - Relationship Has Not Ended
Jennifer Soung, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
• AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Celgene, Eli Lilly, Pfizer, Ortho Dermatologics, Novartis - Speakers Bureau - Relationship Has Not Ended
• AbbVie, Amgen, Arcutis, Eli Lilly, KoBio Labs, Pfizer, Castel Biosciences, Novartis, UCB, Janssen, Dermavant - Contracted Research - Relationship Has Not Ended
• Eli Lilly - Advisory Committee Member - Relationship Has Not Ended
• Arcutis, Bristol Myers Squibb, Dermavant, Novartis - Consulting - Relationship Has Not Ended

Staff at the National Psoriasis Foundation have disclosed no relevant financial relationships with any ineligible companies.

Event Disclosures
Any relevant financial relationships have been mitigated.

Commercial Support
This program is sponsored by UCB and is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $351,404, with 2 percentage funded by CDC/HHS and $14.3 million amount and 98 percentage funded by non-government source(s). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.

ACCREDITATION STATEMENT
• The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.